<i>Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?</i>

Grzegorz Stachowiak; Tomasz Pertyński

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2011
vol. 10

Send email

Copy url:

abstract:

Review paper

Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?

Grzegorz Stachowiak

,

Tomasz Pertyński

Przegląd Menopauzalny 2011; 4: 271–274

Online publish date: 2011/08/30

View full text Get citation

Reduction of estrogen and progestogen doses is one of the main trends in oral menopausal hormone therapy (MHT). Studies on ultra low oral MHT, composed of 0,5 mg estradiol plus reduced doses of various progestoagens (e.g. norethisterone acetate, dydrogesterone), revealed both its high safety profile as well as therapeutic efficacy in alleviating of numerous aliments of the menopausal period.

keywords:

Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?

Grzegorz Stachowiak , Tomasz Pertyński

hormone therapy, ultra low doses, menopause, norethisterone acetate, dydrogesterone

Grzegorz Stachowiak

,

Tomasz Pertyński